[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620211":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":24,"responsibleParty":47,"collaborators":7,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":7,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":7,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","Pathogen-Reduced Platelet Concentrates","Pathogen-reduced platelet concentrates which were either produced from 4, 5 or 8 buffy coats from whole blood donations or which were collected by apheresis.",[14],{"name":15,"affiliation":16,"role":17},"Hubert Schrezenmeier, Prof. Dr. med.","Institut für Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH (DRK-Blutspendedienst Baden-Württemberg Hessen gGmbH und Universitätsklinikum Ulm AöR). Institut für Transfusionsmedizin, Universität Ulm","STUDY_DIRECTOR",[19],{"name":20,"role":21,"phone":22,"phoneExt":7,"email":23},"Simone Hoffmann, Dr. rer. nat.","CONTACT","+497311506897","initiate@blutspende.de",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Institut für Klinische Transfusionsmedizin (IKT) und DRK Blutspendedienst Baden-Württemberg-Hessen\u002F Transfusionsambulanz MVZ DRK-Blutspendedienst Ulm gGmbH","RECRUITING","Ulm","Baden-Wurttemberg","89081","Germany","DE",{"type":34,"coordinates":35},"Point",[36,37],9.99155,48.39841,{"lat":37,"lon":36},[40,44],{"name":41,"role":21,"phone":42,"phoneExt":7,"email":43},"Hubert Schrezenmeier, Prof Dr med.","+49731150500","h.schrezenmeier@blutspende.de",{"name":45,"role":46,"phone":7,"phoneExt":7,"email":7},"Sixten Körper, Dr. med.","PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100620211","pathogen-reduced-platelet-concentrates-experience-in-routine-practice-in-germany-100620211",false,"NCT07354672","Pathogen-Reduced Platelet Concentrates: Experience in Routine Practice in Germany","Pathogen-Reduced Platelet Concentrates: Experience In Routine Practice In Germany","INITIATE","Inclusion Criteria:\n\n* Patients ≥ 18 years\n* Patients who, based on clinical indications\\*, receive at least one platelet transfusion with a pathogen-reduced platelet concentrate for treatment of bleeding risk caused by severe thrombocytopenia resulting from impaired platelet production.\n\n(\\* Taking into account the Cross-sectional Guidelines on the transfusion of blood components and plasma derivatives issued by the German Medical Association (Bundesärztekammer) in its current version.)\n\nExclusion Criteria:\n\nPatients will not be included if they fulfil at least one of the following exclusion criteria:\n\n* Known hypersensitivity to amotosalen HCl or psoralens. In this case, platelet concentrates treated with this pathogen inactivation method should not be used.\n* Known allergies of the recipient to human plasma proteins.\n* Known immune thrombocytopenia.\n* Thrombotic microangiopathy (thrombotic thrombocytopenic purpura; haemolytic uremic syn-drome).\n* Post-transfusion purpura.\n* Heparin-induced thrombocytopenia.\n* Congenital platelet function disorders, such as Glanzmann's thrombasthenia or Bernard- Souli-er syndrome","ALL","18 Years",{"count":60,"type":61},850,"ESTIMATED","OBSERVATIONAL","* Overall objective: to accumulate further experience with the use of pathogen-reduced platelet concentrates throughout the entire process chain from manufacture to clinical use of pathogen-reduced platelet concentrates and their efficacy and safety under real-world conditions. The study aims to better understand the impact of pathogen inactivation on the various steps of the overall supply chain in routine practice, whereby safety, measured in terms of the frequency of serious transfusion reactions and the type, imputability, and outcome of the reactions, is the primary endpoint.\n* Study product: Pathogen-reduced platelet concentrates.\n* Methodology: multi-center, open-label, prospective, non-interventional safety study.",[65],"Platelet Transfusion","2026-01-12",{"date":68,"type":69},"2026-01-21","ACTUAL",{"date":71,"type":69},"2025-12-22",{"date":73,"type":61},"2027-06",{"name":5,"class":6},1]